Horizon Will Submit Krystexxa sBLA To Strengthen Clinical Profile In Gout
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.
You may also be interested in...
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.
Horizon Pharma plc has moved on from its failed $1.7bn attempt to buy Depomed Inc. with the $510m cash purchase of Crealta Holdings LLC, which bought the developer of specialty gout drug Krystexxa (pegloticase) out of bankruptcy two years ago for $120.4m.